Hepatitis B
Coverage of the 2017 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017.
Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.
Full coverage listing by topic
11/30/17
AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- Details
- Category: Liver Cancer/HCC
- Published on Wednesday, 01 November 2017 00:00
- Written by Liz Highleyman
People with hepatitis B virus (HBV) who took an aspirin a day -- often recommended to help prevent cardiovascular disease -- had a lower risk of developing liver cancer, according to a study from Taiwan presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
EASL 2017: WHO Releases Global Hepatitis Report
- Details
- Category: HBV Epidemiology & Mortality
- Published on Monday, 01 May 2017 00:00
- Written by WHO
An estimated 325 million people worldwide are living with chronic hepatitis B or hepatitis C, according to a new report from the World Health Organization (WHO) released at the EASL International Liver Congress last month in Amsterdam.Most lack access to testing and treatment, and therefore are at risk for liver disease progression, liver cancer, and death.
PAS 2017: Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection
- Details
- Category: HBV Vaccines
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
More than half of children treated with immunosuppressive drugs for gastrointestinal or rheumatological conditions no longer had protective levels of antibodies against hepatitis B virus (HBV) and may require repeat vaccinations, according to a study presented at the Pediatric Academic Societies Meeting last week in San Francisco.
Coverage of the 2017 EASL International Liver Congress
- Details
- Category: Hepatitis B
- Published on Sunday, 30 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver, April 19-23, 2017, in Amsterdam.
More Articles...
- Coverage of the 2017 EASL International Liver Conference
- EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- EASL 2017: International Liver Congress Starts This Week in Amsterdam
Web Design and Development by